• MaMT4 Methyltransferase: DNJ Alkaloid Biosynthesis in Mulber

  2026-06-06

  This study characterizes MaMT4, a C/N-selective methyltransferase central to the biosynthesis of 1-deoxynojirimycin-type alkaloids in mulberry leaves. The findings clarify the enzyme's substrate specificity, catalytic mechanism, and role in metabolic engineering strategies for enhanced production of bioactive compounds with antidiabetic potential.

• Translating PLK1 Inhibition: BI 2536 in Next-Gen Oncology

  2026-06-05

  Explore the mechanistic and strategic landscape of BI 2536, a gold-standard PLK1 inhibitor, in translational cancer research. This article bridges rigorous cell cycle biology, actionable experimental design, and future-facing translational guidance, positioning APExBIO’s BI 2536 as a pivotal tool for advancing in vitro and in vivo anticancer studies.

• WAY-100635: A Benchmark 5-HT1A Receptor Antagonist in Neuros

  2026-06-05

  WAY-100635, or N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-N-pyridin-2-ylcyclohexanecarboxamide, is a potent, selective serotonin 5-HT1A receptor antagonist. It exhibits nanomolar affinity and clear antagonist activity in vitro and in vivo, making it a gold standard in neuroscience receptor pharmacology and behavioral research. Its use defines specificity in 5-HT1A studies, while its physicochemical properties guide experimental design.

• Anticoccidial Drugs Reshape Cecal Microbiota in E. tenella-I

  2026-06-04

  This study elucidates how ethanamizuril, sulfachlorpyridazine, and their combination alter the cecal microbiota and metabolome in chickens infected with Eimeria tenella. The findings reveal distinct impacts of these treatments on microbial composition and metabolism, offering new biomarkers for monitoring drug efficacy and poultry health.

• CLCC1 Identified as a Key Host Factor in Herpesvirus Nuclear

  2026-06-04

  The referenced study uncovers CLCC1 as an essential host protein mediating membrane fusion during herpesvirus nuclear egress, a critical step in viral replication that was previously uncharacterized. This discovery opens new avenues for mechanistic research and targeted antiviral strategies, particularly relevant for immunotherapy development.

• HATU in Peptide Synthesis: Mechanism, Selectivity, and Desig

  2026-06-03

  Explore how HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) enables advanced peptide synthesis chemistry, with an emphasis on mechanistic depth, selectivity, and the implications for designing next-generation enzyme inhibitors.

• Dutasteride: Dual 5-Alpha-Reductase Inhibitor for Prostate C

  2026-06-03

  Dutasteride stands out as a dual 5-alpha-reductase inhibitor, enabling precise dissection of androgen-driven mechanisms in prostate cancer and BPH research. This guide details workflow enhancements, troubleshooting tips, and protocol parameters to help researchers maximize the impact of Dutasteride assays for apoptosis and proliferation studies.

• Computational Hapten Design Enables Dual Detection of Mushro

  2026-06-02

  This study introduces a computational strategy for designing haptens and monoclonal antibodies, enabling highly sensitive, simultaneous detection of amatoxins and phallotoxins in mushrooms. The resulting dual-target fluorescent immunoassay offers a robust, rapid approach for mushroom toxin screening and food safety applications.

• Cisplatin in Cancer Research: Mechanisms, Assay Design, and

  2026-06-02

  Explore the multifaceted roles of Cisplatin (CDDP) in cancer research, with an in-depth focus on mechanistic insights, experimental assay design, and the translation of DNA damage pathways into robust chemoresistance studies. Uncover practical decision points for advanced oncology workflows.

• Sodium-Induced Mitochondrial Dysfunction Drives NECSO Cell D

  2026-06-01

  Qiao et al. reveal how sodium influx disrupts mitochondrial energy metabolism to execute necrosis by sodium overload (NECSO). The study links TRPM4-mediated Na+ entry to mitochondrial Ca2+ depletion, impaired oxidative phosphorylation, and cellular energy collapse, providing mechanistic insights with implications for disease models involving disrupted ion homeostasis.

• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-06-01

  Wang et al. identify a METTL16-centered m6A regulatory axis that confers ferroptosis resistance and promotes tumorigenesis in hepatocellular carcinoma (HCC). Their multi-model approach uncovers mechanistic links between RNA methylation, iron metabolism, and therapeutic resistance, highlighting new targets for sensitizing HCC to ferroptosis-based interventions.

• Liproxstatin-1 HCl: Precision Ferroptosis Inhibition in Rese

  2026-05-31

  Liproxstatin-1 HCl empowers researchers to dissect iron-dependent cell death mechanisms with nanomolar precision and high selectivity. From unraveling mitochondrial calcium's role in ferroptosis to optimizing acute renal failure and hepatic injury models, this guide delivers actionable protocols and advanced troubleshooting for reliable, translational results.

• COX-2 Pathway and Revascularization After Bothropic Venom In

  2026-05-30

  This study elucidates the dual-phase role of the cyclooxygenase-2 (COX-2) pathway in muscle tissue ischemia and revascularization following injury by Bothrops asper venom. Using temporally controlled inhibition with Lumiracoxib, the research demonstrates that early COX-2 inhibition exacerbates ischemia but later enhances angiogenic mediator release and vascular remodeling, providing mechanistic insight for muscle regeneration models.

• Applied Strategies for Belinostat (PXD101) in Cancer Researc

  2026-05-29

  Belinostat (PXD101) is a benchmark pan-HDAC inhibitor, distinguished by robust, quantifiable effects in bladder and prostate cancer models. This guide unpacks practical workflows, optimization tactics, and lessons from advanced in vitro methodologies to help researchers maximize reproducibility and biological insight.

• RBMS1 Loss Enables PD-L1 Checkpoint Blockade in TNBC

  2026-05-29

  This study uncovers RBMS1 as a key regulator that maintains PD-L1 stability in triple-negative breast cancer (TNBC), showing that RBMS1 depletion sensitizes tumors to immune checkpoint blockade. The findings highlight a new mechanism for overcoming immune resistance in TNBC and suggest avenues for combinatorial immunotherapeutic strategies.

442 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page